Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Cencora (formerly AmerisourceBergen) is one of the three largest pharmaceutical wholesalers in the United States, distributing branded and generic drugs to retail pharmacies, hospitals, and physician practices. The company operates a high-volume, low-margin distribution network with approximately 50 distribution centers across North America, handling over 20 million prescription deliveries monthly. Competitive position is driven by scale economics, manufacturer rebate agreements, and specialty pharmaceutical distribution capabilities including oncology and rare disease therapies.
Cencora earns thin margins (3.2% gross, 1.1% operating) on massive volume throughput, generating returns through rapid inventory turnover (15-20x annually) and working capital efficiency. Revenue comes from distribution fees charged to pharmacies/hospitals, manufacturer rebates tied to volume commitments, and specialty pharmacy services commanding higher margins (8-12% vs 2-3% for generic distribution). Pricing power is limited due to oligopolistic competition with McKesson and Cardinal Health, but scale advantages create barriers through logistics infrastructure, IT systems integration with pharmacy customers, and manufacturer relationships. The 101.4% ROE reflects aggressive financial leverage (4.15x debt/equity) applied to asset-light operations.
Specialty pharmaceutical revenue growth rates, particularly oncology and biosimilar distribution volumes
Generic drug pricing environment and manufacturer rebate agreements renegotiation outcomes
Opioid litigation settlement progress and reserve adequacy (multi-billion dollar exposure)
Pharmacy customer consolidation and contract renewals with major chains (CVS, Walgreens, independent networks)
Medicare Part D and Medicaid reimbursement policy changes affecting pharmacy economics
Ongoing opioid litigation with potential for settlements exceeding $6.6B already accrued, creating earnings volatility and cash flow uncertainty through 2030s
Amazon Pharmacy and vertical integration by CVS/Walgreens into distribution could disintermediate traditional wholesaler model over 5-10 year horizon
Government drug pricing reform (Medicare negotiation expansion, Medicaid rebate increases) compressing manufacturer margins and potentially reducing rebate pools available to distributors
Biosimilar adoption accelerating could disrupt high-margin specialty distribution economics as products commoditize
Oligopoly structure with McKesson and Cardinal Health leads to intense competition for customer contracts, limiting pricing power and margin expansion
Manufacturer direct-to-pharmacy distribution models bypassing wholesalers for high-value specialty products
Consolidation among pharmacy customers (CVS-Aetna, Walgreens-VillageMD) increasing buyer negotiating leverage
High financial leverage (4.15x debt/equity) creates refinancing risk and limits financial flexibility during industry disruption
Current ratio of 0.92 indicates working capital intensity and reliance on short-term credit facilities for daily operations
Pension obligations and opioid settlement payment schedules creating long-term cash flow commitments
Covenant compliance risk if EBITDA deteriorates due to margin compression or litigation charges
low - Pharmaceutical demand is highly inelastic with minimal correlation to GDP growth. Prescription volumes are driven by demographics (aging population), disease prevalence, and drug innovation rather than economic cycles. However, generic drug pricing can face deflationary pressure during economic weakness as payers negotiate aggressively, and elective specialty treatments may see modest volume softness during severe recessions.
Rising interest rates increase financing costs on the $29B debt load (4.15x leverage), directly pressuring net margins given the thin 0.5% net margin profile. Each 100 bps rate increase impacts annual interest expense by approximately $290M pre-tax. Higher rates also compress valuation multiples for low-growth, leveraged business models. However, pharmaceutical distribution cash flows are relatively stable, providing some insulation. The company typically maintains floating rate exposure on 30-40% of debt.
Moderate credit exposure through accounts receivable from retail pharmacies and health systems, with DSO typically 25-30 days. Independent pharmacy bankruptcies during credit tightening can create bad debt expense, though major chain customers (investment grade rated) represent 60%+ of revenue. The company's own credit profile (BBB rated) affects commercial paper and revolver costs used for working capital financing.
value - The stock trades at 0.2x sales and generates 4.6% FCF yield, attracting value investors seeking stable cash flows in defensive healthcare sector. The 50.9% one-year return suggests momentum investors have recently participated, likely driven by opioid litigation clarity and specialty growth acceleration. Dividend yield of approximately 1.5-2.0% provides modest income component. Not a growth stock given single-digit revenue growth and margin constraints, but appeals to investors seeking healthcare exposure with lower volatility than biotech or med-tech.
moderate - Beta typically 0.8-1.0 reflecting defensive healthcare characteristics offset by financial leverage and litigation headline risk. Daily volatility lower than broader market due to stable pharmaceutical demand, but quarterly earnings can see 5-10% moves on contract announcements or litigation developments. The 22.7% six-month return vs -0.8% three-month return indicates recent consolidation after strong run.
